You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test.
The firm said its test detects biomarkers inside monocyte blood cells that reflect the reduced clearance of amyloid-beta plaque that leads to Alzheimer's disease.
The companies aim to identify biomarkers that can be used to diagnose early-onset Parkinson's disease, as well as track disease progression.
The test is designed to detect and visualize abnormal phosphorylated alpha-synuclein — a hallmark of synucleinopathies — in cutaneous nerve fibers.
The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.